Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
5.44
+0.08 (1.49%)
At close: Sep 26, 2025, 4:00 PM EDT
5.50
+0.06 (1.10%)
After-hours: Sep 26, 2025, 7:34 PM EDT
Abeona Therapeutics Employees
Abeona Therapeutics had 136 employees as of December 31, 2024. The number of employees increased by 52 or 61.90% compared to the previous year.
Employees
136
Change (1Y)
52
Growth (1Y)
61.90%
Revenue / Employee
$2,941
Profits / Employee
$420,897
Market Cap
278.96M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ABEO News
- 25 days ago - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Abeona Therapeutics Inc. (ABEO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Abeona Therapeutics: AAV204 Capsid Could Be Next Growth Prospect Beyond Zevaskyn - Seeking Alpha
- 6 weeks ago - Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - GlobeNewsWire
- 2 months ago - AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients - GlobeNewsWire
- 2 months ago - ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - GlobeNewsWire
- 2 months ago - Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy - PRNewsWire